15 November 2022.
This workshop followed a series of events on design approaches for current and future HIV prevention efficacy trials. It brought together industry and non-industry representatives who have a stake in HIV vaccine R&D to explore how biomarkers can be used as surrogate markers of clinical efficacy in counterfactual vaccine trials.
By debating the design of future efficacy trials, the workshop aimed to contribute to addressing the industry’s concern that, in a changing prevention landscape, conducting efficacy trials can be an obstacle to investment in HIV vaccine R&D.
